Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin consolidation versus observation after first-line CHOP-R in diffuse large B-cell lymphoma
2005-001727-11Phase 3Terminated
- Sponsor
- Schering AG
- Start
- Feb 2006
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Zevalin study regimen with Observation (2 arms). Primary endpoint: Overall survival. Started Feb 2006; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2005-001727-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001727-11.